mesobiliverdin: can be mixture of alpha & beta isomers; RN given refers to (beta)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
mesobiliverdin : A bilin that consists of 3,18-diethyl-2,7,13,17-tetramethyl-1,19,22,24-tetrahydro-21H-biline-8,12-dipropanoic acid bearing two oxo substituents at positions 1 and 19. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
ID Source | ID |
---|---|
PubMed CID | 6443754 |
CHEBI ID | 36748 |
SCHEMBL ID | 4321506 |
MeSH ID | M0120281 |
Synonym |
---|
mesobiliverdin |
SCHEMBL4321506 |
3-[(2z,5z)-2-[[3-(2-carboxyethyl)-5-[(z)-(3-ethyl-4-methyl-5-oxopyrrol-2-ylidene)methyl]-4-methyl-1h-pyrrol-2-yl]methylidene]-5-[(4-ethyl-3-methyl-5-oxopyrrol-2-yl)methylidene]-4-methylpyrrol-3-yl]propanoic acid |
21h-biline-8,12-dipropanoic acid, 3,18-diethyl-1,19,22,24-tetrahydro-2,7,13,17-tetramethyl-1,19-dioxo- |
493-88-9 |
mesobiliverdin ix beta |
mesobiliverdin ix |
mesobilivedin ix alpha |
mesobiliverdin ixalpha |
8,12-bis(2-carboxyethyl)-3,18-diethyl-2,7,13,17-tetramethylbilin-1,19(21h,24h)-dione |
3,18-diethyl-2,7,13,17-tetramethyl-1,19-dioxo-1,19,22,24-tetrahydro-21h-biline-8,12-dipropanoic acid |
3,18-diethyl-1,19,22,24-tetrahydro-2,7,13,17-tetramethyl-1,19-dioxo-21h-biline-8,12-dipropanoic acid |
CHEBI:36748 |
3-[2-[[3-(2-carboxyethyl)-5-[(3-ethyl-4-methyl-5-oxopyrrol-2-ylidene)methyl]-4-methyl-1h-pyrrol-2-yl]methylidene]-5-[(4-ethyl-3-methyl-5-oxopyrrol-2-yl)methylidene]-4-methylpyrrol-3-yl]propanoic acid |
CS-0185978 |
HY-W127808 |
mesobiliverdin (microbial source) |
Mesobiliverdin IXα is a naturally occurring bilin analog of HO-1 catalytic product biliverdin VIII.
Excerpt | Reference | Relevance |
---|---|---|
"Mesobiliverdin IXα is a naturally occurring bilin analog of HO-1 catalytic product biliverdin IXα." | ( Mesobiliverdin IXα ameliorates osteoporosis via promoting osteogenic differentiation of mesenchymal stem cells. Chang, CT; Lin, YY; Peng, CA; Takemoto, JY, 2022) | 2.89 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 3 (27.27) | 18.7374 |
1990's | 1 (9.09) | 18.2507 |
2000's | 3 (27.27) | 29.6817 |
2010's | 2 (18.18) | 24.3611 |
2020's | 2 (18.18) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.34) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 1 (9.09%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 10 (90.91%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |